Abstract To study variations of Epstein-Barr virus (EBV), we analyzed the gp350/220 gene for several cell lines and Japanese wild isolates using direct sequencing. The N-terminal region was highly conserved in all EBVs except for Jijoye/P3HR-1 and a few isolates. The variation of the region coincided with EBV types A and B (also referred to as types 1 and 2) and were, respectively, designated as the types a and b. The type A/a was detected in most Japanese cell lines and wild isolates, and was classified as China1 type with latent membrane protein (LMP) 1 gene. The type B/b was detected in only a few wild isolates with the Med and China2 types. The C-terminus had more diversity than the N-terminus and lacked the divergence between types A/a and B/b. The phylogenetic analyses of the gp350/220 and LMP1 genes may suggest a mode of EBV evolution into types A/a and B/b and then to LMP1 subtypes.
Introduction
Epstein-Barr virus (EBV) causes infectious mononucleosis (IM) and is closely associated with Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and various malignant and non-malignant diseases [1] . Furthermore, EBV is a ubiquitous virus and is considered to be associated with autoimmune diseases such as systemic lupus erythematosus [2] , Sjögren's syndrome [3] , rheumatoid arthritis [4, 5] , multiple sclerosis [6] , and uveitis [7] . On the other hand, EBV has unapparent infection in most of the human population.
Epstein-Barr virus genomic diversity might be an explanation for EBV's association with various diseases. Sequence variations in EBV nuclear antigen (EBNA) 1, EBNA2, EBNA3, latent membrane protein (LMP) 1, and other viral proteins have been reported [1] . We previously analyzed the nucleotide sequences of LMP1 and viral IL-10 (vIL-10) genes and detected specific race-and geographydependent variations [8, 9] , although vIL-10 gene was highly conserved with only a few specific sequence variations.
We specifically examined the EBV major envelope protein gp350/220 (BLLF1) gene in this study to further elucidate the genomic variations of EBV. B lymphocyte (B cell) is a main target of EBV infection. The EBV infection to B cells is initiated by binding of the gp350/220 and a B-cell surface receptor, CD21, which is known as complement receptor-2 (CR2) or C3d receptor [10] . Then viral gp42 binds to B-cell surface protein HLA class II, which triggers B-cell fusion [11] . The gp350 is transcribed from the BamHI-L fragment of EBV in the BLLF1 reading frame and gp220 is produced by alternative splicing of the transcript [12] . The N-terminal 470-amino-acid region of gp350/220 contains the B-cell binding domain; the N-terminal 470-amino-acid gp220 derivative blocked EBV adsorption and infection; also, EBV-neutralizing monoclonal antibody (mAb) 72A1, which inhibits EBV binding and invasion of host cells, recognizes the N-terminal 470-amino-acid region [13] . Furthermore, the N-terminus 9-amino-acid sequence of gp350/220 EDPGFFNVE corresponds to an 11-amino-acid sequence of C3dg EDPGKQLYNVE. The peptide binds to purified CR2 and CR2 positive, but not negative, B and T cell lines [14] . Urquiza et al. reported that the 9-amino-acid regions and two other peptide regions, of gp350/220 region, bound to CR2 positive cells, were recognized by 72A1 mAb, and inhibited 72A1 mAb binding to EBV, so they were inferred to be involved in EBV binding to B cells [15] .
For this study, we mainly analyzed the nucleotide sequence of the N-terminal gp350/220 region in EBVpositive cell lines and Japanese-EBV wild isolates. The sequences of the N-terminal region were highly conserved in majority of isolates; however, a distinct homologous variation was detected in Jijoye, P3HR-1, and two wild isolates of minority isolates. The former has been classified as type A (type 1) EBV and the latter as type B (type 2) EBV by the analysis of the EBNA2 gene. The C-terminal region has more variations than the N-terminal region, which suggests that the C-terminal region might have received more mutations than the N-terminal region along viral evolution.
Materials and methods

Cell lines and clinical samples
This study was approved by the Medical Ethics Committee for Human Subject Research at the Faculty of Medicine, Tottori University. For this study, 11 EBV-positive cell lines, B95-8 [16] , P3HR-1 [17] , Jijoye [18] , Raji [19] , Akata [20] , Daudi [21] , OB [22] , EB1 [23] , Namalwa [24] , NPC-KT [25] , and SNU-719 [26] were used. All cell lines were cultured in RPMI1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) with penicillin (100 IU ml -1 ), streptomycin (100 lg ml -1 ), and 10% fetal bovine serum in CO 2 incubator at 37°C. The GC specimens were obtained from seven patients in Japan [8] . All specimens were confirmed as EBV genome positive by polymerase chain reaction (PCR) findings using a BamHI-W-specific primer pair [27] and by in situ hybridization for EBVencoded small RNA (EBER) [28] . Throat-washing (TW) samples were obtained from healthy volunteers at the Faculty of Medicine, Tottori University. The TW samples were confirmed as EBV genome positive using PCR. The peripheral blood mononuclear cells (PBMCs) of patients with uveitis and healthy volunteers were collected, respectively, at the Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, and from employees and students. The PBMCs were isolated using Lymphosepar I (Immuno-Biological Laboratories Co. Ltd., Fujioka, Japan), confirmed to be EBV genome positive using the PCR method with a BamHI-K specific primer pair, 5 0 -TGAATCATGTCTGACGAGGG-3 0 and 5 0 -CAAC TTGGACGTTTTTGGGG-3 0 , and by Southern-hybridization using the BamHI-K-specific probe 5 0 -ATGTGTCT CCCTTCTCTCCTAGG-3 0 , and subsequently used for this examination.
DNA preparation
Cells, GC tissues, and TWs were digested with proteinase K (100 lg ml -1 ) in 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM EDTA, and 0.1% SDS at 55°C for 90 min. The DNA was extracted with phenol/chloroform and precipitated by ethanol, then dissolved in TE (10 mM TrisHCl, pH 8.0, 1 mM EDTA), as described previously [29] . The DNA of PBMCs was extracted using columns (QIAamp DNA Mini Kit; Qiagen Inc., Hilden, Germany) according to the manufacturer's protocol.
Direct sequencing of PCR products
Nested PCR was performed using six primer pairs to analyze the sequence variation in gp350/220 gene ( Table 1) . A thermal cycler (MP TP-3000; Takara Bio Inc., Ohtsu, Japan) was used for PCR. In the first PCR, 500 nmol gpW-S, gpW-A primers, 1 unit of Ex Taq polymerase (Takara Bio Inc.), and 250 lM dNTP mixture were added and filled up to 10 ll with H 2 O. The five lg, 10 lg, and 50 lg DNAs of cell lines, GC tissues and TW, and PBMCs were used, respectively, for the template DNA. Then PCR was performed, respectively, in one cycle for 5 min at 94°C, and in 25-28 cycles for 30 s at 94°C, 62°C, and 3 min at 72°C. The PCR products were electrophoresed in 1% agarose gel, stained with ethidium bromide, confirmed as to the molecular size, then purified using a gel extraction kit (QIAEX II; Qiagen Inc.) or columns (MicroSpin S-400 HR; GE Healthcare, Buckinghamshire, UK). Each PCR product, diluted 1,000-fold, was used as a template for the 2nd PCR, which were all carried out using the five primer pairs described above, except for primer gpW-S and gpW-A. The PCR conditions consist of one cycle for 5 min at 94°C, 25 cycles for 30 s at 94°C, 30 s at 63-66°C, and 1 min at 72°C. The PCR products were purified using a column (MicroSpin S-400 HR) and used as templates of sequence reactions. The sequence reactions were performed in a reaction volume of 10 ll consisting of 10-100 ng of these products, 2 ll of primers used in the PCR reaction described above (diluted to 1.6 pmol ll -1 each), 4 ll of Big Dye Terminator Cycle Sequencing FS ReadyReaction (Applied Biosystems, Foster, USA), and H 2 O under the following conditions: 25 cycles for 10 s at 96°C, 10 s at 50°C, and 4 min at 60°C. After cycle sequencing, reaction products were purified using Sephadex G-50 DNA grade F (GE Healthcare); then Genetic analyzer (3100; Applied Biosystems) was used for sequence determination. Sequencing was carried out for each sample at least twice. Data of alignments were analyzed using software (Genetyx version 8; Genetyx Corp., Tokyo, Japan) to confirm the result. The method of sequencing in the C-terminus of LMP1 was described in a previous report [8] .
Analysis of the EBV type A or B
For EBV typing into A and B, nested PCR was performed using EBNA2-specific primers described previously [30] . The first PCR was carried out with a common sense and antisense primer pair, and performed in one cycle for 5 min at 94°C, and in 25-30 cycles for 30 s at 94°C, 60°C, and 1 min at 72°C. The first reaction products of 5 lg (cell lines), 10 lg (GC and TW), and 50 lg (PBMCs) were transferred to nested reaction tubes containing type A and B EBV-specific primers. The 2nd PCR was performed in one cycle for 5 min at 94°C, and in 20-25 cycles for 30 s at 94°C, 60°C, and 55°C for type A and type B specific primers, respectively, and 1 min at 72°C. The amplified products were electrophoresed in 1.5% agarose gel and detected as EBV type A or type B based on their molecular size.
Phylogenetic analysis
To analyze the phylogenetic relationship the N-terminal region (1-483) and the entire region of gp350/220 were used, respectively. The PHYLIP formatted files were produced as reported previously [8] . Phylogenetic trees were constructed from PHYLIP formatted files using software [Tree View (Win32) 1.6.6; http://taxonomy.zoology.gla. ac.uk/tod/rod.html].
Results
Sequence variations in the N-terminal region of gp350/220
We analyzed the N-terminal region (nucleotide sequence 1-1450; amino acid sequence 1-483) of the gp350/220 gene in various EBV isolates using direct sequencing of the PCR products. First, we confirmed that our nucleotide sequence to B95-8 EBV was identical to those in the NCBI (nucleotide: V01555). As the standard of B95-8 sequence, we compared the nucleotide sequences of EBV DNA from 10 cell lines (African BL-Raji, EB1, Jijoye, P3HR-1, Daudi, Namalwa; Korean GC-SNU-719; Japanese B cell-OB; Japanese BL-Akata; Japanese NPC-NPC-KT), 19 Japanese wild isolates [7 GC tissues, 6 TW samples, and 6 PBMCs of uveitis patients (PB-U1, -U2, -U3) and of healthy subjects (PB-H1, -H2, -H3)] using software (Genetyx SV/RC ver.8; Genetyx Corp.) ( Table 2 ). The nucleotide sequences were highly conserved in most of them, except for several point mutations (data not shown). However, a remarkable mutation was detected in the EBV DNA from Jijoye and the cell clone P3HR-1. The nucleotide sequences of Jijoye and P3HR-1 were identical (data not shown) and the specific mutations were detected in the ten amino acids at regions of 17, 20, 21, 31, 38, 48, 60, 62, 67, and 115. The same mutation was also detected in two Japanese wild isolates, TW19 and PB-H3, while it was not detected in any other isolate. A mutation was detected at amino acid 201 from E to Q, in 24 of 29 tested samples (82.8%). Of 22 Japanese isolates, 20 (90.9%) and 3 of 6 African BL (50%) carried the mutation. A mutation was detected at amino acid 252 from A to V, in 13 Japanese isolates of 22 samples (59.1%), but not in any of the six African BL cell lines. A mutation was detected at amino acid 434 from L to S, in 17 Japanese isolates of 22 samples (77.3%). A mutation at amino acid 441 from D to A was detected in 24 of 29 samples (82.8%). No characteristic mutation in BL, GC, TW, and PBMC from uveitis patients and healthy subjects was detected.
We conclude that the N-terminal region of gp350/220, especially on the sequence of 1-200 amino acids, is highly conserved. However, a clear difference is apparent in the nucleotide alignment, which is distinctly classifiable into two types of sequences with B95-8 and Jijoye/P3HR-1. We designated them, respectively, as type a and type b. We analyzed seven other TW isolates (TW20-26) to this region; all of them were confirmed as type a (data not shown). Among EBV isolates from Japanese people, type a is clearly major and type b is minor.
Close relationship between EBV types determined by the sequence of the N-terminal region of gp350/220 and EBNA2 genes
The alignments of Jijoye and P3HR-1 corresponded mutually; they had many mutations and distinctive alignments to B95-8 and others (Table 2) . Also, B95-8 and Jijoye/P3HR-1 were, respectively, classified in type A and type B EBV by the EBNA2 gene [31] . This result corresponded to the previous report of divergence of gp350/220 between type A EBV (B95-8) and type B EBV (Jijoye, P3HR-1 and AG 876) [32] . Results showed that TW19 and PB-H3 had alignment extremely approximated to Jijoye/ P3HR-1, except for an amino-acid mutation, at 117 from T to A. We analyzed the type of EBV for the EBNA 2 region using the PCR method (Fig. 1) . B95-8 and Jijoye were used, respectively, as controls of type A and type B EBV. Type A was detected in Akata and SNU719, but no type A or type B was detected in P3HR-1, which has a deletion of the EBNA2 gene [33] . Results showed that PB-H3 carried the type B EBNA2 gene. In addition, TW19 was also found to carry the type B EBNA2 gene; however, all 24 other wild isolates turned out to carry the type A gene (data not shown). The result indicates that EBV is clearly distinguishable as two types of B95-8 (type a) and Jijoye/P3HR-1 (type b), according to the variations of the N-terminus of gp350/220 which directly links to type A and type B with the EBNA2 gene ( Table 3 ). Variations of the N-terminus of gp350/220 were shown using a phylogenetic analysis (Fig. 2) . Type A/a and type B/b are on separate and distant branches, which implies a different evolution of EBV.
Comparison between gp350/220 and LMP1 sequences On variations of LMP1, EBV was classified into seven types: B95-8, China1, China2, China3, Med, NC, and AL [34] , and had specific variations depending on race and geographical location [8, 35] . We characterized that B95-8 was in B95-8 type, Raji, EB1, P3HR-1, and Jijoye were in African and Namalwa and Daudi were in Med type, and Akata was in China1 type [8] . We analyzed the LMP1 nucleotide sequences in isolates in this study ( Table 4) . The Japanese isolates were all classified into China1, except for Med type of TW19 and China2 type of PB-H3 (Table 3) according to the classification [34] . No relationship was found for the classification of EBV by the N-terminal region of gp350/220 and LMP1. However, it is noteworthy that all Japanese isolates were type A/a and belonged to China1 type, except for TW19 and PB-H3, which were type B/b and belonged, respectively, to Med type and China2 type. 
Comparative genotyping of EBV isolates by gp350/220, EBNA2, and LMP1 genes. The genotypings of gp350/220, EBNA2, and LMP1 were made according to the divergence of N-terminal region of gp350/220 sequence analysis, by PCR analysis of EBNA2 and of C-terminal region of LMP1 sequence. ND shows no detection by the method used in this experiment
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The whole encoding region of the gp350/220 sequence
We analyzed the whole gp350/220 amino-acid sequence in B95-8, Jijoye, P3HR-1, Akata, TW19, and PB-H3 (Fig. 3) . Total amino acids of B95-8, Jijoye/P3HR-1 (identical), Akata, TW19, and PB-H3 were, respectively, 907, 886, 856, 886, and 876. Total 37 amino-acid mutations were detected in the gp350/220 genes. Three binding sites, peptide-1 (aa: 16-29), -2 (aa: 142-161), and -3 (aa: 282-301) are located in the N-terminus of gp350/220 to the EBV receptor of CD21 [14, 15] . The mutation was not detected in any EBV isolates except for Jijoye/P3HR-1, TW19, and PB-H3 in the sites. The mutation was detected at three segments (H to Q, G to R, and E to D) in peptide-1 site of Jijoye/P3HR-1, TW19, and PB-H3, but not in peptide-2 and peptide-3. The C-terminal region of gp350/220 had more mutations than the N-terminal region. A long repeat region of amino acid 508-641 was located in the splicing region of gp350/gp220. The sequences of Jijoye/ P3HR-1, Akata, TW19, and PB-H3, but not B95-8 had six common mutations (aa 495, W to R; aa 525, P to S; aa 613, G to S; aa 642, Q to P; aa 672, N to I; and aa 754, Q to K) and a deletion (aa 509-522). Akata and PB-H3 had four common mutations (aa 534, A to G; aa 648, A to D; aa 657, I to R; and aa 805, G to D) and a deletion (aa 678-686). This deletion was detected in many Japanese wild isolates and expected to be characteristic of them (unpublished data). On the other hand, Jijoye/P3HR-1 and TW19 had identical C-terminus sequences. Their differences were seen only at amino acid 117 in the whole gp350/220 sequence. Phylogenetic trees using the whole amino-acid sequence of gp350/220 were produced (Fig. 4) . They were clearly separated to two branches of type A/a and type B/b. They were further separated in Akata (China1) and B95-8 (B95-8), and PB-H3 (China2), TW19 (Med) and P3HR-1 (African) branches. The upper branches of Akata and PB-H3 had the 9-amino-acid deletion, but not in the lower branches of B95-8, P3HR-1 and TW19 (Fig. 3) . This result suggests the EBV evolution to the separation of type A/a and type B/b, and then to subtypes.
Discussion
We demonstrated that the N-terminal region of gp350/220 gene was highly conserved with only a few amino acid changes. The conservation of the N-terminal region may be a key to EBV survival, for it remains unchanged despite the Fig. 2 Phylogenetic tree drawn from N-terminal sequences of gp350/ 220 of the cell lines and Japanese wild isolates using neighbor joining method. EBV type a and type b are indicated. The scale portrays the evolutionary distance Table 4 Amino-acid sequence variation of C-terminus of LMP1 Amino acid  309  322  323  326  327  328  329  331  333  334  335  338  344  346  352 355 366
Numbers across the top correspond to the amino-acid positions. Names in the left column refer to the individual isolates. Only sequences different from B95-8 are indicated. The amino acids are donated by capital letters. An asterisk indicates a deletion of an amino acid long evolutional periods. The gp350/220 protein has extensive N-and O-glycosylation that is supposed to preserve the virus. Recently, the X-ray crystal structure of gp350/220 with the bulky polyglycans composed of N-linked glycosylation was demonstrated [36] . The authors suggested that the polyglycans may provide virions with the protection from proteolysis during viral transmission and generate a disguise for evading the immune response. We considered about the conservation of the gp350/220 gene based on host immune response to EBV infection. The surviving strategy of EBV is to establish latency in humans and the infected host attempts to remove the infected virus and cells by the antibodies and/or the cytotoxic T lymphocytes (CTL). Against the immune attack EBV mutates viral genes and evades it. The mutation of the EBV genome has been reported in latent and lytic genes [1] . Recently, whole EBV genome sequences of the three EBV strains were compared to single nucleotide polymorphisms and the mutations were frequently detected in the latent but very little in the lytic genes [37] . This suggests that the main mutation of EBV genome could be induced mostly to latent proteins by the immune attack of CTL. The CTL target to gp350/220 has been rarely reported [38] .
To the N-terminal region of gp350/220, we found more mutation in the C-terminal region (Fig. 3) . It may imply the association with the mutation that CTL target epitopes of gp350/220 were detected in the C-terminal, but not in N-terminal regions [38] . The C-terminal region comprises extra-cellular, transmembranous, and intracellular domains [12] and most mutations and the deletion of gp350/220 are located in the repeat region, which is spliced out in gp220 [12] . In the C-terminal region, four representatives EBVs P3HR-1, Akata, TW19, and PB-H3 had a common mutation with 6-amino-acids. In addition, Japanese-EBV Akata and PB-H3 had one deletion with 9-amino-acids. The common mutation and deletion were detected in many Japanese-EBV isolates (unpublished data). However, another Japanese isolate, TW19, had the common mutation but did not have the deletion, and had the identical sequence as P3HR-1, except for one mutation. This type of virus was rarely detected in wild isolates in Japan (unpublished data).
We found that among 22 Japanese isolates, only two (TW19 and PB-H3) had the same sequence to Jijoye/ P3HR-1 in the N-terminal region of gp350/220, with a difference of 1 or 2 amino acids ( Table 2) . We determined that most Japanese isolates were type A; however, only TW19 and PB-H3 were type B. Although type A is overwhelmingly predominant throughout the world, except for Africa and New Guinea, a high prevalence of type B was found in lymphomas of immunocompromised hosts [39] . In Japan, type B is also minor and the incidence is estimated as 1-5% [40] [41] [42] [43] , although the type B was detected with a high frequency in patients with pyothorax-associated lymphoma [44] . Type A and type B differ in their capabilities of transforming B cells, with which EBNA2 function is associated [45] ; and the type B had poor immortalization ability of B cell [31] , while type A (B95-8) and type B (P3HR-1) show similar adsorption to Raji cells [46] . It has been reported as the divergence between B95-8 as type A and Jijoye/P3HR-1 as type B [32] . We propose that the divergence in N-terminus of gp350/220 has the potential for application to EBV typing (type a and type b) because no exception was found in our results.
Epstein-Barr virus is classified into seven strains by variations of the LMP1 gene [34] . We previously reported that African and Japanese EBVs were phylogenetically much different and that Chinese and Japanese EBVs were similar on the LMP1 patterns [8, 35] . The classification on LMP1 gene was totally different from the EBV typing (type A/a and type B/b) based on EBNA2 and gp350/220. However, in our study, most Japanese isolates carried type A/a and China1,and only TW19 and PB-H3 were type B/b and were, respectively, Med and China 2 on the LMP1 (Table 3) . Thus the type B/b, as the minority in Japan, had also the minority on LMP1 type. Taken together, the divergences of EBNA2, gp350/220, and LMP1 may demonstrate the track of EBV evolution.
We propose a hypothetical model of the EBV evolution inferred from the variations of EBNA2, gp350/220, and LMP1 genes. The type A/a and type B/b diverged, respectively, to such as Akata and B95-8, and to PB-H3, TW19 and P3HR-1 (Fig. 4) . The types diverged further on the 9-amino-acid deletion of the C-terminal region, which was detected in most Japanese isolates Akata, PB-H3 and others, but not in B95-8, TW19, and P3HR-1. On the LMP1 typing the former indicate the major strains in East Asian areas, such as China, Japan, and Alaska, and the latter in Africa and Mediterranean Sea areas. Thus EBV may have separated into type A/a and type B/b and subsequently each evolve into a different subtype (B95-8, African, China1, China2, China3, Med, NC, and AL) categorized by the polymorphism of LMP1 gene [8, 34, 35] ; each virus has been migrated with the human race to different regions, and may be associated with various diseases such as IM, BL, NPC, and others in human beings. This hypothesis will be cleared by following more EBV samples of the various diseases in different areas of the world. In addition to our hypothesis, we have to consider a recent issue that the evolution on EBV genome is complexity with recombining lineages at the whole EBV genome [37] .
In conclusion, N-terminal regions of gp350/220 are highly conserved in EBV isolates of different origin. Distinct differences of the sequence alignments pertain between type A/a and type B/b EBV in the N-terminal region. The C-terminal region has more variations than the N-terminal region and exhibits the lack of characteristic divergence between type A/a and type B/b EBV. The gp350/220 and LMP1 genes may suggest a mode of evolution of EBV into types A/a and B/b, and then to subtypes by the HLA-restricted CTL. Strong conservation in the N-terminal region could be helpful as a preventive strategy against EBV infection.
